Sawai Group Holdings Co., Ltd. (SWGHF)
- Previous Close
11.52 - Open
11.52 - Bid 9.94 x 40000
- Ask 12.62 x 40000
- Day's Range
11.52 - 11.52 - 52 Week Range
11.52 - 13.81 - Volume
120 - Avg. Volume
2 - Market Cap (intraday)
1.498B - Beta (5Y Monthly) -0.01
- PE Ratio (TTM)
15.57 - EPS (TTM)
0.74 - Earnings Date Aug 7, 2025 - Aug 11, 2025
- Forward Dividend & Yield 0.37 (3.22%)
- Ex-Dividend Date Sep 29, 2025
- 1y Target Est
--
Sawai Group Holdings Co., Ltd., together with subsidiaries, engages in the research and development, manufacturing, and marketing of generic pharmaceuticals. The company offers generic drugs in various dosage forms, including tablets, oral dispersing tablets, capsules, granules, injectables, tapes, ophthalmic or nasal solutions, syrups, and other forms for various therapeutic areas comprising cardiovascular, gastro-intestinal, blood/body fluid, other metabolic, antibiotics, central nervous system, antiallergics, anti-cancer, urogenital organs and anus, chemotherapeutic and antineoplastic agents, respiratory system, etc., as well as vitamin preparations. It sells its generic drugs through distributors, wholesalers, and retailers in Japan and the United States. Sawai Group Holdings Co., Ltd. was founded in 1929 and is headquartered in Osaka, Japan.
www.sawaigroup.holdings--
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: SWGHF
View MorePerformance Overview: SWGHF
Trailing total returns as of 5/28/2025, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SWGHF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SWGHF
View MoreValuation Measures
Market Cap
1.50B
Enterprise Value
1.85B
Trailing P/E
15.58
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.08
Price/Book (mrq)
1.03
Enterprise Value/Revenue
1.40
Enterprise Value/EBITDA
7.29
Financial Highlights
Profitability and Income Statement
Profit Margin
12.14%
Return on Assets (ttm)
3.56%
Return on Equity (ttm)
6.52%
Revenue (ttm)
189.02B
Net Income Avi to Common (ttm)
13.14B
Diluted EPS (ttm)
0.74
Balance Sheet and Cash Flow
Total Cash (mrq)
41.27B
Total Debt/Equity (mrq)
49.42%
Levered Free Cash Flow (ttm)
40.96B